Day One

Wednesday September 24th 2014

 

8.00 Breakfast and Registration 

  

 

..........................................................................................................................................................................................................

8.20 Chair's Welcome Address 

   Janine Schuurman
VP Research
Genmab

..........................................................................................................................................................................................................

8.30 How can the Lessons Learned from DVD-Ig™ Platform Development be Applied to Other Bispecific Molecules? 

  • The structural and functional aspects of the DVD-Ig™ format
  • Potential implications of structural aspects of various bi– (dual-) specific formats on functional outcomes
  • Design of “new” bi- and multi-specific antibody-based formats
  
Tariq Ghayur
Senior Research Fellow
Abbvie

..........................................................................................................................................................................................................

9.00 Designing and Discovering Transformative Bispecific Antibody Therapeutics 

  • CrossMab technology to generate bispecific antibodies by IgG domain exchange that retain its IgG-like properties
  • pREDs innovative Brain Shuttle technology increases the delivery of therapeutics across the blood-brain barrier
  • Combing common light chain approaches and novel display technologies to discover cooperative pairs of antibodies
   Martin Steegmaier
Head, Discovery Unit, LMR
Roche

..........................................................................................................................................................................................................

9.30 Speed Networking & Morning Refreshments 

The Speed Networking sessions are the most valuable hour you’ll spend at the conference and a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the field and establish meaningful business relationships..

..........................................................................................................................................................................................................

Discovery Stream   Development Stream
Uncovering Target Biologies Amenable to Multispecific Therapy 
     Progressing Your Lead Through to Successful
Proof-of-Concept 

 

11.00 A Novel Bispecific Antibody Targeting EGFR and cMET with Multiple Mechanisms of Action 

  • Rationale for selecting EGFR-cMet pair for bispecific targeting
  • Preclinical data supporting multiple mechanisms of action of JNJ-61186372
  • Preclinical efficacy of JNJ-61186372 in several in vivo models
Sheri Moores, Principal Scientist, Janssen
  

 

11.00 Testing Strategies for the Assessment of Bispecific T Cell-Engaging BiTE® Antibodies 

  • Performing effective assessments of BiTE ® constructs during preclinical development
  • Translating lessons learned into optimized testing strategies

Benno Rattel, Executive Director, Nonclinical Development, Amgen Research (Munich) GmbH

11.30 Complexity of Bispecific Antibodies Targeting Cell Surface Receptors 

  • Safety and efficacy implications in designing bsAbs engaging cell surface receptors 

  • Structural and development properties in selecting the right drug development candidate

Jijie Gu, Principal Scientist, Abbvie

  

11.30 Development of MM141-dual inhibitor of IGF-1R and ErbB3

  • Engineering and optimization of drug-like properties beyond just efficacy to create more stable constructs
  • Ensuring candidates have good manufacturability attributes, and can be effectively formulated
  • Ways to create scalable and robust manufacturing processes

Neeraj Kohli, Associate Director, Merrimack

..........................................................................................................................................................................................................

12.00 Networking Lunch

..........................................................................................................................................................................................................

1.30 Addressing Challenges to Transporting Antibodies Across the Blood-Brain Barrier 

  • A bispecific antibody platform targeting TfR improves antibody transport across the BBB
  • BBB uptake mediated by TfR is robust and non-exhaustible
  • Recent data demonstrate the safety and efficacy of the TfR bispecific antibody technology in multiple animal models

James Ernst, Senior Scientist, Genentech

  

1.30 An IL-23/IL-17A/F Bispecific Antibody Demonstrates Efficacy and Biophysical Properties Favorable for Development

  • An overview of a multispecific antibody as a potential innovative therapeutic for inflammatory disorders
  • Biophysical and production properties similar to traditional antibodies
  • Efficacy demonstrated in marmoset EAE model

Brenda Stevens, Senior Scientist, BMS

2.00 Development of B Lymphocyte Targeted Bispecific DART Molecules for the Treatment of Autoimmune Disorders

  • MGD010 is a half-life extended bispecific DART protein that coligates the inhibitory Fcγ receptor IIb (CD32B) and the B cell receptor component, CD79B, on B cells
  • CD32B x CD79B DARTs engage CD32B in a BCR-dependent manner and inhibit B cell activation without B cell depletion
  • In vitro and in vivo safety, PK and efficacy studies that support the initiation of clinical development of MGD010 will be presented
Syd Johnson, VP, Antibody Engineering, Macrogenics
  

2.00 Current Challenges and Opportunities in Toxicity Assessment of Multispecific Biologics 

  • How to determine whether there is an appropriate non-clinical species to test safety liabilities
  • Importance of understanding target expression/distribution and biology for all targets
  • Integration of nonclinical data to enable first in-human dose selection

Rodney Prell, Senior Toxicologist, Genentech


2.30 Panel: Why use a Bispecific in the First Place? 

  • Is it possible to identify target criteria for different format types?
  • Challenge of finding novel target pairs
  • Defining optimal antigen expression patterns

Selected conference speakers and attendees

 

2.30 Panel: How can we Improve the Predictability of Preclinical Research in Preparation for In-Human Testing ?

  • Developing reliable disease models
  • Effective assays to test proof-of-concept studies
  • What else do we need?

Selected conference speakers and attendees

..........................................................................................................................................................................................................

3.00 Afternoon Refreshments

..........................................................................................................................................................................................................

3.30 Chair’s Stream Summaries 

   Janine Schuurman
VP Research
Genmab

..........................................................................................................................................................................................................

Creating Superior Bispecific Compounds

..........................................................................................................................................................................................................

3.45 ADAPTIRTM Molecules: Unique Biology From A Flexible Bispecific Platform 

  • Emergent’s ADAPTIRTM (modular protein technology) platform of bispecific protein therapeutics has unique and distinguishing properties compared to other bispecific antibody formats. 
  • Key applications include redirection of T cell cytotoxicity with induction of minimal cytokine release compared to other formats.
  • Our lead bispecific molecule from this RTCC program, ES414 for treatment of metastatic castration-resistant prostate cancer is targeting filing an IND in second half of 2014
 

John W. Blankenship
Lead Scientist, Applied Research and Non-Clinical Development,
Emergent BioSolutions

 

..........................................................................................................................................................................................................

 

4.15 Strategies and Challenges in Analytical Testing of Nanobody-Based Multispecifics 

  • Implications for the development of analytical methods
  • Focus on methods to assess product quality and stability for in-process and release samples
  • Analytical challenges for product characterization
   Ann Brige,
Team Leader, CMC Analytic, Ablynx

..........................................................................................................................................................................................................

4.45 T-cell dependent bispecific antibodies (TDBs) as potential therapy in B cell malignancies

  • Bispecific designs based on "knob" and "hole" heterodimerization sites in the CH3 domains of two antibody heavy chains
  • Using X-ray crystallography to better understand the knob-into-hole interface, the molecular mechanism of heterodimerization, and to engineer Fc domains that could improve the assembly and purity of the construct
  

Liping Laura Sun, Ph.D.
Senior Research Associate
Genentech

..........................................................................................................................................................................................................

5.15 Drinks Reception & Networking 

..........................................................................................................................................................................................................